Development of High-expressing Ion Channels for Research and Therapeutic Applicat

Information

  • Research Project
  • 8775955
  • ApplicationId
    8775955
  • Core Project Number
    R43GM112181
  • Full Project Number
    1R43GM112181-01
  • Serial Number
    112181
  • FOA Number
    PA-11-335
  • Sub Project Id
  • Project Start Date
    9/5/2014 - 10 years ago
  • Project End Date
    5/31/2016 - 8 years ago
  • Program Officer Name
    COLE, ALISON E.
  • Budget Start Date
    9/5/2014 - 10 years ago
  • Budget End Date
    8/31/2015 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/2/2014 - 10 years ago
Organizations

Development of High-expressing Ion Channels for Research and Therapeutic Applicat

DESCRIPTION (provided by applicant): Ion channels, such as Kv1.3 and Nav1.7, are involved in a number of human disorders, including autoimmunity and pain that affect >100 million Americans annually and are poorly treated. However, ion channels are typically exceptionally difficult to express at high levels due to their structural complexity and toxicity. s a result, many research and therapeutic applications for these targets have been very limited where high-levels of membrane protein are required. For example, for human voltage-gated potassium (Kv) and sodium (Nav) ion channels, there are no solved crystal structures and no therapeutic monoclonal antibodies (MAbs) approved by the FDA or even in clinical trials, despite the high level of pharmaceutical interest in such MAbs as therapeutics. These applications all typically require high levels of protein expression, and the expression of most ion channels is usually orders of magnitude below what is required for success. Here we propose to develop a versatile platform for expressing high levels of conformational ion channel proteins. Our use of this platform within the scope of this proposal will be for isolating unique MAbs against Kv1.3 and Nav1.7. We expect that this platform will be extensible to other ion channels and will also have utility for structural research, high-throughput screening, and as biomedical research reagents.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    264005
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:264005\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INTEGRAL MOLECULAR
  • Organization Department
  • Organization DUNS
    034055645
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191045504
  • Organization District
    UNITED STATES